Denali Therapeutics Inc. DNLI Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s accrued expenses?
- Denali Therapeutics Inc. (DNLI) reported accrued expenses of $9.22M in Q1 2026.
- How has Denali Therapeutics Inc.'s accrued expenses changed year-over-year?
- Denali Therapeutics Inc.'s accrued expenses increased by 20.4% year-over-year, from $7.66M to $9.22M.
- What is the long-term trend for Denali Therapeutics Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s accrued expenses has grown at a -7.4% compound annual growth rate (CAGR), from $47.15M to $32.18M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.